Article thumbnail

Alleviation of Brain Hypoperfusion after Preventative Treatment with Lomerizine in an Elderly Migraineur with Aura

By Joe Aoyagi, Ken Ikeda, Tetsuhito Kiyozuka, Takehisa Hirayama, Yuichi Ishikawa, Ryuta Sato, Yasuhiro Yoshii, Kiyokazu Kawabe and Yasuo Iwasaki

Abstract

Previous studies of brain single-photon emission tomography (SPECT) showed changes of regional cerebral blood flow (rCBF) in migraineurs during prodromes or headache attacks. Little is known about how successful medication of migraine prevention can reflect rCBF in migraineurs. We highlighted alternation of brain SPECT findings in a migraineur with aura before and after prophylactic treatment with lomerizine, a calcium channel blocker. A 70-year-old man with migraine developed visual disturbance frequently at walking exercise for the recent 3 months. After this visual attack, a mild-degree of throbbing headache occured occasionally. Brain SPECT using 99mTc-ethyl cysteinate dimer was performed at interictal time of migraine. Brain SPECT before lomerizine treatment revealed hypoperfusion in the frontal, parietal, and occipital regions. He was diagnosed with recurrence of migraine with aura (MA). Lomerizine (10 mg/day, po) was administered for 3 months. MA and visual aura without headache were dramatically improved. Migraine attacks and visual disturbance were not induced at exercise. At 3 months after lomerizine medication, brain SPECT showed remarkable increase of rCBF. These SPECT changes of our patient indicated that antimigraine mechanism of lomerizine could contribute to restoration of cerebral hypoperfusion

Topics: Case Report
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3065840
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1995). A quantitative approach to technetium-99m ethyl cysteinate dimer: a comparison with technetium-99m hexamethylpropylene amine oxime,”
  2. (1994). Basilar artery migraine reversible ischemia demonstrated by Tc-99m4
  3. (1997). Basilar artery migraine: transcranial doppler EEG and SPECT from the aura phase to the end,” Headache,
  4. (1994). Brain perfusion scintigraphy with 99mTc ethylcysteinate dimer for migraine accompagnee,”
  5. (2007). Do the effects of long-term lomerizine administration differ with age?”
  6. (2010). e l t ,C .A .B a r t l e t t ,A .R .H a r v e y ,S .A .D u n l o p ,a n dM . Fitzgerald, “Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine,”
  7. (1995). Effects of Ca channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats,”
  8. (1988). Effects of KB-2697, a new calcium antagonist, and other diphenylpiperazines on [3H]nitrendipine binding,”
  9. (1995). F e r r a r i ,J .H a a n ,J .A .K .B l o k l a n de ta l . ,“ C e r e b r a l blood flow during migraine attacks without aura and effect of sumatriptan,”
  10. (1981). Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine,”
  11. (2009). Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery,”
  12. (1997). Interictal and ictal phase study with Tc
  13. (1990). J.Olesen,L.Friberg,T.S.Olsenetal.,“Timingandtopography of cerebral blood flow, aura, and headache during migraine attacks,”
  14. (1995). Kutsuzawa et al., “Clinical evaluation of KB-2796 (lomerizine hydrochloride) on migraine: late phase II study,”
  15. (1984). M.LauritzenandJ.Olesen,“Regionalcerebralbloodflowduring migraine attacks by Xenon-133 inhalation and emission tomography,”
  16. (1999). Selective effects of lomerizine, a novel diphenylmethylpiperazine Ca 2+ channel blocker, on cerebral blood flow
  17. (1995). Tashiro et al., “Clinical evaluation of lomerizine on migraine: double-blind study in comparison with demetotiazine,”
  18. (1995). Tashiro et al., “Long-term trial of lomerizine hydrochloride for migraine,”
  19. (2008). The effects of magnesium prophylaxis
  20. (2002). Usefulness of a three-dimensional stereotaxic ROI template on anatomically standardised 99mTc-ECD SPET,”